Vancouver, British Columbia, March 1, 2007 –Protox TM Therapeutics Inc. (TSX-V:PRX) announced today the company's key milestones for the coming year that will help position the company as a leader in targeted therapeutics for cancer and other proliferative diseases. They include the completion of a Phase I study in prostate cancer, the initiation of a Phase I study in benign prostatic hyperplasia and the initiation of a Phase IIb study in brain cancer.
